Mike Raab, Ardelyx
Ardelyx chops a third of its staff after stock-crushing failure in chronic kidney disease
A couple of weeks after the FDA turned down Ardelyx’s chronic kidney disease candidate, shocking analysts and CEO Mike Raab, the company is axing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
